flucytosine has been researched along with Cancer of Prostate in 28 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The indication is local recurrence of prostate cancer after definitive radiation therapy." | 2.70 | Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. ( Aguilar-Cordova, E; Barton, K; Brown, S; DePeralta-Venturina, M; Freytag, SO; Khil, M; Kim, JH; Lu, M; Menon, M; Nafziger, D; Paielli, D; Peabody, J; Pegg, J; Stricker, H, 2002) |
| "Metastatic prostate cancer causes significant morbidity and mortality and there is a critical unmet need for effective treatments." | 1.43 | PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. ( Banerjee, SR; Bhujwalla, ZM; Chen, Z; Krishnamachary, B; Penet, MF; Pomper, MG, 2016) |
| "CD-MSC toxicity on murine prostate cancer cells and tumour tropism were verified in vitro and ex-vivo before starting the preclinical studies." | 1.40 | Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression. ( Abrate, A; Altaner, C; Benigni, F; Bettiga, A; Buono, R; Canu, T; Cavarretta, IT; Colciago, G; Del Maschio, A; Esposito, A; Guazzoni, G; Hedlund, P; Lucianò, R; Montorsi, F, 2014) |
| "Prostate cancer is the most common malignancy among men." | 1.39 | Cytosine deaminase-expressing human neural stem cells inhibit tumor growth in prostate cancer-bearing mice. ( Cha, YJ; Doo, SW; Kim, DH; Kim, JH; Kim, SU; Lee, HJ; Song, YS, 2013) |
| "The risk of prostate cancer has been increasing in men by degrees." | 1.38 | Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells. ( Choi, KC; Hwang, KA; Kim, SU; Kim, YB; Yi, BR, 2012) |
| " In order to assess the value of suicidal gene therapy on human prostate carcinoma, the authors studied the toxic effects of HSV-TK gene and CD-TK fusion gene systems on prostate carcinoma cell line PC-3m." | 1.32 | [Toxic effects of HSV-TK and CD-TK suicidal gene systems on prostate carcinoma cells]. ( Liu, CS; Ma, DX; Xu, CX; Xu, ZS; Zhang, DQ; Zhang, HQ, 2003) |
| "LNCaP human prostate cancer cells were co-transfected with these 2 plasmids and luciferase activity was measured to assess promoter activities." | 1.31 | Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. ( Hayakawa, M; Ikegami, S; Suzuki, S; Tadakuma, T; Yoshimura, I, 2002) |
| "Established prostate cancer cell lines are eventually infectible by adenoviral vector." | 1.31 | Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit. ( Deisseroth, A; Fu, S; Nanakorn, T; Wang, X; Won, J; Yin, L, 2001) |
| " In situ transduction of the CD gene, followed by systemic use of 5-FC at a daily dosage of 300 mg/kg for 14 days, was performed two days later." | 1.31 | In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models. ( Yin, L; Zhang, Y; Zhang, Z; Zhao, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 20 (71.43) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrate, A | 1 |
| Buono, R | 1 |
| Canu, T | 1 |
| Esposito, A | 1 |
| Del Maschio, A | 1 |
| Lucianò, R | 1 |
| Bettiga, A | 1 |
| Colciago, G | 1 |
| Guazzoni, G | 1 |
| Benigni, F | 1 |
| Hedlund, P | 1 |
| Altaner, C | 2 |
| Montorsi, F | 1 |
| Cavarretta, IT | 2 |
| Chen, Z | 1 |
| Penet, MF | 1 |
| Krishnamachary, B | 1 |
| Banerjee, SR | 1 |
| Pomper, MG | 1 |
| Bhujwalla, ZM | 1 |
| Marignol, L | 1 |
| Foley, R | 1 |
| Southgate, TD | 1 |
| Coffey, M | 1 |
| Hollywood, D | 1 |
| Lawler, M | 1 |
| Khatri, A | 3 |
| Husaini, Y | 1 |
| Ow, K | 2 |
| Chapman, J | 2 |
| Russell, PJ | 3 |
| Xing, L | 1 |
| Sun, X | 1 |
| Deng, X | 1 |
| Kotedia, K | 1 |
| Urano, M | 1 |
| Koutcher, JA | 1 |
| Ling, CC | 1 |
| Li, GC | 1 |
| Altanerova, V | 1 |
| Matuskova, M | 1 |
| Kucerova, L | 1 |
| Culig, Z | 1 |
| Lu, M | 3 |
| Freytag, SO | 4 |
| Stricker, H | 3 |
| Kim, JH | 4 |
| Barton, K | 2 |
| Movsas, B | 1 |
| Yi, BR | 1 |
| Hwang, KA | 1 |
| Kim, YB | 1 |
| Kim, SU | 2 |
| Choi, KC | 1 |
| Lee, HJ | 1 |
| Doo, SW | 1 |
| Kim, DH | 1 |
| Cha, YJ | 1 |
| Song, YS | 1 |
| Khil, M | 1 |
| Peabody, J | 2 |
| Menon, M | 1 |
| DePeralta-Venturina, M | 2 |
| Nafziger, D | 1 |
| Pegg, J | 2 |
| Paielli, D | 2 |
| Brown, S | 2 |
| Aguilar-Cordova, E | 1 |
| Corban-Wilhelm, H | 2 |
| Hull, WE | 1 |
| Becker, G | 2 |
| Bauder-Wüst, U | 1 |
| Greulich, D | 2 |
| Debus, J | 2 |
| Yoshimura, I | 2 |
| Ikegami, S | 1 |
| Suzuki, S | 2 |
| Tadakuma, T | 2 |
| Hayakawa, M | 2 |
| Kato, H | 1 |
| Koshida, K | 1 |
| Yokoyama, K | 1 |
| Mizokami, A | 1 |
| Namiki, M | 1 |
| Zhang, DQ | 1 |
| Xu, CX | 1 |
| Xu, ZS | 1 |
| Ma, DX | 1 |
| Zhang, HQ | 1 |
| Liu, CS | 1 |
| Pradhan, DG | 1 |
| Xia, X | 1 |
| Ehemann, V | 1 |
| Braun, K | 1 |
| Pandha, HS | 1 |
| Cook, D | 1 |
| Greenhalgh, R | 1 |
| Dalgleish, A | 1 |
| Boucher, PD | 1 |
| Im, MM | 1 |
| Shewach, DS | 1 |
| Zhang, B | 1 |
| Doherty, E | 1 |
| Pwint, H | 1 |
| Martiniello-Wilks, R | 1 |
| Blackburn, RV | 2 |
| Galoforo, SS | 2 |
| Corry, PM | 2 |
| Lee, YJ | 3 |
| Anello, R | 1 |
| Cohen, S | 1 |
| Atkinson, G | 1 |
| Hall, SJ | 1 |
| Uchida, A | 1 |
| O'Keefe, DS | 1 |
| Bacich, DJ | 1 |
| Molloy, PL | 1 |
| Heston, WD | 1 |
| Yin, L | 2 |
| Fu, S | 1 |
| Wang, X | 1 |
| Nanakorn, T | 1 |
| Won, J | 1 |
| Deisseroth, A | 1 |
| Lee, H | 1 |
| Borrelli, MJ | 1 |
| Zhang, Z | 1 |
| Zhang, Y | 1 |
| Zhao, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile[NCT00583492] | Phase 2 | 44 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Phase II Study Evaluating HSV-tk + Valacyclovir Gene Therapy in Combination With Androgen Deprivation Therapy, Brachytherapy, External Beam Radiotherapy, and Prostatectomy for High-Risk Prostate Cancer[NCT03541928] | Phase 2 | 60 participants (Anticipated) | Interventional | 2018-08-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This metric includes both expected and unexpected events Toxicities were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3 (NCT00583492)
Timeframe: 90 days
| Intervention | percentage of adverse events (Number) |
|---|---|
| Gene Therapy + IMRT | 4.6 |
| IMRT Alone | 6.0 |
Quality of Life was measured using the comprehensive Expanded Prostate Cancer Index Composite (EPIC) instrument 19 and 20 (NCT00583492)
Timeframe: 3 years
| Intervention | participants (Number) |
|---|---|
| Gene Therapy + IMRT | 0 |
| IMRT Alone | 0 |
(NCT00583492)
Timeframe: 10 years
| Intervention | participants (Number) |
|---|---|
| Gene Therapy + IMRT | 21 |
| IMRT Alone | 23 |
Biochemical/Clinical Failure was defined as PSA nadir plus 2 ng/mL (NCT00583492)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Gene Therapy + IMRT | 20 |
| IMRT Alone | 21 |
(NCT00583492)
Timeframe: 10 years
| Intervention | participants (Number) |
|---|---|
| Gene Therapy + IMRT | 21 |
| IMRT Alone | 23 |
(NCT00583492)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Gene Therapy + IMRT | 6 |
| IMRT Alone | 11 |
1 review available for flucytosine and Cancer of Prostate
| Article | Year |
|---|---|
Novel gene-directed enzyme prodrug therapies against prostate cancer.
Topics: Animals; Antineoplastic Agents; Bystander Effect; Clinical Trials as Topic; Combined Modality Therap | 2006 |
3 trials available for flucytosine and Cancer of Prostate
24 other studies available for flucytosine and Cancer of Prostate
| Article | Year |
|---|---|
Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression.
Topics: Adenocarcinoma; Animals; Cell Movement; Cytosine Deaminase; Disease Models, Animal; Flucytosine; Gen | 2014 |
PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.
Topics: Animals; Antigens, Surface; Antimetabolites; Bacteria; Cell Line, Tumor; Cytosine Deaminase; DNA; Dr | 2016 |
Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro.
Topics: Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Flucytosine; Genetic Therapy; Gen | 2009 |
Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Cytokines; Cyto | 2009 |
Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells.
Topics: Animals; Blotting, Western; Bystander Effect; Cell Line, Tumor; Coculture Techniques; Cytosine Deami | 2009 |
Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth.
Topics: Animals; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorouracil; Humans; Male; Mesenchymal | 2010 |
Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.
Topics: Animals; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell S | 2012 |
Cytosine deaminase-expressing human neural stem cells inhibit tumor growth in prostate cancer-bearing mice.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Survival; Cell Track | 2013 |
Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy.
Topics: Animals; Antimetabolites; Bystander Effect; Cell Survival; Cytosine Deaminase; Disease Models, Anima | 2002 |
Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cytosine Deaminase; Enhancer Elements, Genet | 2002 |
Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: experimental study.
Topics: Animals; Antimetabolites; Combined Modality Therapy; Cytosine Deaminase; Flucytosine; Fluorouracil; | 2002 |
[Toxic effects of HSV-TK and CD-TK suicidal gene systems on prostate carcinoma cells].
Topics: Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Ganciclovir; Genetic Therapy; Humans; Male; Prost | 2003 |
Comparison of different methods to assess the cytotoxic effects of cytosine deaminase and thymidine kinase gene therapy.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Escherichia col | 2004 |
Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy.
Topics: Animals; Antimetabolites; Apoptosis; Cancer Vaccines; Cell Line, Tumor; Cytosine Deaminase; Flucytos | 2005 |
A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy.
Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytosine Deaminase; | 2006 |
Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Genetic Therapy; Green Fluore | 2006 |
Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells.
Topics: Adenoviridae; Antimetabolites; Antiviral Agents; Cytosine Deaminase; Enzyme Activation; Escherichia | 1998 |
Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity.
Topics: Adenoviridae; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma | 1999 |
Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation.
Topics: Adenoviridae; Animals; Antimetabolites; Cell Survival; Cytosine Deaminase; Escherichia coli; Flucyto | 2000 |
Suicide gene therapy on LNCaP human prostate cancer cells.
Topics: Antimetabolites; Antiviral Agents; Cytosine Deaminase; Escherichia coli; Flucytosine; Ganciclovir; G | 2001 |
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
Topics: Adenocarcinoma; Animals; Cytosine Deaminase; Flucytosine; Gene Expression; Genes, Reporter; Genetic | 2001 |
Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit.
Topics: Adenoviridae; Animals; Antimetabolites; Bystander Effect; Cell Survival; Cytosine Deaminase; Dose-Re | 2001 |
Gene transfer into human prostate adenocarcinoma cells with an adenoviral vector: Hyperthermia enhances a double suicide gene expression, cytotoxicity and radiotoxicity.
Topics: Adenocarcinoma; Adenoviridae; Antiviral Agents; Cell Survival; Cytosine Deaminase; Drug Synergism; F | 2002 |
In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models.
Topics: Adenoviridae; Animals; Cell Division; Cytosine Deaminase; Disease Models, Animal; Flucytosine; Lymph | 2002 |